File No: STD/1524

July 2015

NATIONAL INDUSTRIAL CHEMICALS NOTIFICATION AND ASSESSMENT SCHEME (NICNAS)

PUBLIC REPORT

Ethane, 1-ethoxy-2-(2-methoxyethoxy)-

This Assessment has been compiled in accordance with the provisions of the *Industrial Chemicals (Notification and Assessment) Act 1989* (the Act) and Regulations. This legislation is an Act of the Commonwealth of Australia. The National Industrial Chemicals Notification and Assessment Scheme (NICNAS) is administered by the Department of Health, and conducts the risk assessment for public health and occupational health and safety. The assessment of environmental risk is conducted by the Department of the Environment.

For the purposes of subsection 78(1) of the Act, this Public Report may be inspected at our NICNAS office by appointment only at Level 7, 260 Elizabeth Street, Surry Hills NSW 2010.

This Public Report is also available for viewing and downloading from the NICNAS website or available on request, free of charge, by contacting NICNAS. For requests and enquiries please contact the NICNAS Administration Coordinator at:

Street Address: Level 7, 260 Elizabeth Street, SURRY HILLS NSW 2010, AUSTRALIA.

Postal Address: GPO Box 58, SYDNEY NSW 2001, AUSTRALIA.

TEL: + 61 2 8577 8800 FAX: + 61 2 8577 8888 Website: www.nicnas.gov.au

Director NICNAS

TABLE OF CONTENTS

SUMMARY		3
CONCLUSIO	NS AND REGULATORY OBLIGATIONS	3
ASSESSMEN	T DETAILS	6
1.	APPLICANT AND NOTIFICATION DETAILS	6
2.	IDENTITY OF CHEMICAL	6
3.	COMPOSITION	7
4.	PHYSICAL AND CHEMICAL PROPERTIES	7
5.	INTRODUCTION AND USE INFORMATION	8
6.	HUMAN HEALTH IMPLICATIONS	9
6.1.	Exposure Assessment	
6.1.1		
6.1.2		
6.2.	Human Health Effects Assessment	
6.3.	Human Health Risk Characterisation	14
6.3.1	Occupational Health and Safety	14
6.3.2		
7.	ENVIRONMENTAL IMPLICATIONS	15
7.1.	Environmental Exposure & Fate Assessment	15
7.1.1	· · · · · · · · · · · · · · · · · · ·	
7.1.2	•	
7.1.3		
7.2.	Environmental Effects Assessment	
7.2.1		
7.3.	Environmental Risk Assessment	
	PHYSICAL AND CHEMICAL PROPERTIES	
	TOXICOLOGICAL INVESTIGATIONS	
B.1.	Acute toxicity – oral	
B.2.	Acute toxicity – dermal	
B.3.	Irritation – skin (1)	
B.4.	Irritation – skin (2)	
B.5.	Irritation – eye	
B.6.	Skin sensitisation	
B.7.	Repeat dose toxicity – 14 day range-finding	
B.8.	Repeat dose toxicity – 42-day study, combined with reproductive/developmental toxicity	
	screening	23
B.9.	Genotoxicity – bacterial reverse mutation test (1)	
B.10.	Genotoxicity – bacterial reverse mutation test (2)	
B.11.	Genotoxicity – simplified <i>in vitro</i> mammalian chromosome aberration test	
B.12.	Genotoxicity – <i>in vitro</i> mammalian chromosome aberration test	
B.13.	Genotoxicity – <i>in vivo</i> mammalian erythrocyte micronucleus test	
	ENVIRONMENTAL FATE AND ECOTOXICOLOGICAL INVESTIGATIONS	
C.1.	Environmental Fate	
C.1.1		
C.2.	Ecotoxicological Investigations	
C.2.1		
C.2.2		
C.2.3		
	PHY	

SUMMARY

The following details will be published in the NICNAS Chemical Gazette:

ASSESSMENT REFERENCE	APPLICANT(S)	CHEMICAL OR TRADE NAME	HAZARDOUS CHEMICAL	INTRODUCTION VOLUME	USE
STD/1524	Epson Australia Pty Ltd	Ethane, 1-ethoxy-2- (2-methoxyethoxy)-	Yes	≤ 5 tonnes per annum	Solvent in printing inks

CONCLUSIONS AND REGULATORY OBLIGATIONS

Hazard classification

Based on the available information, the notified chemical is recommended for hazard classification according to the *Globally Harmonised System of Classification and Labelling of Chemicals (GHS)*, as adopted for industrial chemicals in Australia. The recommended hazard classification is presented in the table below.

Hazard classification	Hazard statement
Flammable Liquids Category 4	H227 – Combustible liquid.
Reproductive Toxicity Category 2	H361 – Suspected of damaging fertility or the unborn child.
Suspected Human Reproductive Toxicant	

Based on the available information, the notified chemical is recommended for hazard classification according to the *Approved Criteria for Classifying Hazardous Substances* (NOHSC, 2004) as a substance toxic to reproduction Category 3 with the following risk phrase:

R62/63: Possible risk of impaired fertility/Possible risk of harm to the unborn child

Human health risk assessment

Provided that the recommended controls are being adhered to, under the conditions of the occupational settings described, the notified chemical is not considered to pose an unreasonable risk to the health of workers.

When used in the proposed manner, the notified chemical is not considered to pose an unreasonable risk to public health.

Environmental risk assessment

On the basis of the PEC/PNEC ratio and the assessed use pattern, the notified chemical is not considered to pose an unreasonable risk to the environment.

Recommendations

REGULATORY CONTROLS

- The notified chemical should be classified as follows:
 - Flammable Liquids Category 4: H227 Combustible liquid.
 - Reproductive Toxicity Category 2 Suspected Human Reproductive Toxicant: H361 Suspected of damaging fertility or the unborn child.

The above should be used for products/mixtures containing the notified chemical, if applicable, based on the concentration of the notified chemical present and the intended use/exposure scenario.

- The (M)SDS provided by the notifier should be amended as follows:
 - Revise the information for the notified chemical in Sections 2 and 3 to include the hazard classification for reproductive toxicity.
 - Revise Section 8.2.2.2(c) respiratory protection to state:

"Not required unless engineering controls are inadequate to control inhalation exposure (refer to Section 8.3 for ventilation recommendations)."

- The notifier should comply with relevant State and Territory OHS labelling requirements.
- NICNAS will refer the notified chemical to Safe Work Australia, for their consideration.

CONTROL MEASURES

Occupational Health and Safety

- A person conducting a business or undertaking at a workplace should implement the following engineering controls to minimise occupational exposure to the notified chemical as introduced in the ink cartridges, during printing processes:
 - Local exhaust ventilation or other mechanical ventilation (as specified in Safe Work Australia Guidance Control guidance sheet P39 Wide-format inkjet printing with solvent-borne inks) if inhalation exposure may occur.
- A person conducting a business or undertaking at a workplace should implement the following safe
 work practices to minimise occupational exposure during handling of the notified chemical as
 introduced in the ink cartridges, during printing processes:
 - Avoid contact with skin and eyes
 - Avoid breathing in vapours
 - Compliance with Safe Work Australia Guidance Control guidance sheet P39 Wide-format inkjet printing with solvent-borne inks
- A person conducting a business or undertaking at a workplace should ensure that the following personal
 protective equipment is used by workers to minimise occupational exposure to the notified chemical as
 introduced in the cartridges:
 - Coveralls
 - Disposable gloves if dermal exposure to the ink may occur
 - Respiratory protection if engineering controls are inadequate to control inhalation exposure

Guidance in selection of personal protective equipment can be obtained from Australian, Australian/New Zealand or other approved standards.

- A copy of the (M)SDS should be easily accessible to employees.
- If products and mixtures containing the notified chemical are classified as hazardous to health in accordance with the *Globally Harmonised System of Classification and Labelling of Chemicals (GHS)* as adopted for industrial chemicals in Australia, workplace practices and control procedures consistent with provisions of State and Territory hazardous substances legislation should be in operation.

Disposal

Where reuse or recycling are not available or appropriate, dispose of the notified chemical in an
environmentally sound manner in accordance with relevant Commonwealth, state, territory and local
government legislation

Emergency procedures

 Spills or accidental release of the notified chemical should be handled by physical containment, collection and subsequent safe disposal.

Regulatory Obligations

Secondary Notification

This risk assessment is based on the information available at the time of notification. The Director may call for the reassessment of the chemical under secondary notification provisions based on changes in certain

circumstances. Under Section 64 of the *Industrial Chemicals (Notification and Assessment) Act (1989)* the notifier, as well as any other importer or manufacturer of the notified chemical, have post-assessment regulatory obligations to notify NICNAS when any of these circumstances change. These obligations apply even when the notified chemical is listed on the Australian Inventory of Chemical Substances (AICS).

Therefore, the Director of NICNAS must be notified in writing within 28 days by the notifier, other importer or manufacturer:

- (1) Under Section 64(1) of the Act; if
 - the notified chemical is imported in any form other than as a component of printing ink at up to 25% concentration in sealed cartridges;
 - the ink containing the notified chemical is used for printing in other than commercial facilities.

or

- (2) Under Section 64(2) of the Act; if
 - the function or use of the chemical has changed from a solvent in printing inks, or is likely to change significantly;
 - the amount of chemical being introduced has increased, or is likely to increase, significantly;
 - the chemical has begun to be manufactured in Australia;
 - additional information has become available to the person as to an adverse effect of the chemical on occupational health and safety, public health, or the environment.

The Director will then decide whether a reassessment (i.e. a secondary notification and assessment) is required.

(Material) Safety Data Sheet

The (M)SDS of the notified chemical and a product containing the notified chemical provided by the notifier were reviewed by NICNAS. The accuracy of the information on the (M)SDS remains the responsibility of the applicant.

ASSESSMENT DETAILS

1. APPLICANT AND NOTIFICATION DETAILS

APPLICANT(S)

Epson Australia Pty Ltd (ABN: 91 002 625 783)

3 Talavera Rd

NORTH RYDE NSW 2113

NOTIFICATION CATEGORY

Standard: Chemical other than polymer (more than 1 tonne per year)

EXEMPT INFORMATION (SECTION 75 OF THE ACT)

No details are claimed exempt from publication.

VARIATION OF DATA REQUIREMENTS (SECTION 24 OF THE ACT)

Variation to the schedule of data requirements is claimed as follows: acute inhalation toxicity and bioaccumulation.

PREVIOUS NOTIFICATION IN AUSTRALIA BY APPLICANT(S)

None

NOTIFICATION IN OTHER COUNTRIES

USA

2. IDENTITY OF CHEMICAL

MARKETING NAME(S)

Epson Ink Cartridge T6871 (product containing the notified chemical)

CAS NUMBER

1002-67-1

CHEMICAL NAME

Ethane, 1-ethoxy-2-(2-methoxyethoxy)-

OTHER NAME(S)

HISOLVE EDM

Diethylene glycol methyl ethyl ether

DEGMEE

MOLECULAR FORMULA

 $C_7H_{16}O_3$

STRUCTURAL FORMULA

H₃C O O CH₃

MOLECULAR WEIGHT

148.2 Da

ANALYTICAL DATA

METHOD FT-IR

Remarks Measured with a NICOLET 6700 FT-IR equipped with F.S. Thunder Dome ATR (Thermo

Fisher Scientific Inc, Waltham USA) and results consistent with structure of the notified

chemical

TEST FACILITY Unknown

METHOD FT-IR (non-GLP)

Remarks Measured with a FTIR 8400-S spectrophotometer quipped with a MKII Golden Gate Single

Reflection ATR System (Shimadzu, Japan) and results consistent with structure of the

notified chemical

TEST FACILITY WIL (2014a)

METHOD UV-Vis Absorption

Remarks UV-Vis absorption spectra in water under neutral, acidic and alkaline conditions were

obtained using a spectrophotometer. No absorbance maximum was observed.

TEST FACILITY WIL Research (2014b)

METHOD NMR

Remarks Measured with a 400MHz Varian spectrometer (Varian, USA) and results consistent with

structure of the notified chemical

TEST FACILITY WIL Research (2013)

3. COMPOSITION

DEGREE OF PURITY

99.98%

HAZARDOUS IMPURITIES/RESIDUAL MONOMERS

None

NON HAZARDOUS IMPURITIES/RESIDUAL MONOMERS (> 1% BY WEIGHT)

None

ADDITIVES/ADJUVANTS

None

4. PHYSICAL AND CHEMICAL PROPERTIES

APPEARANCE AT 20 °C AND 101.3 kPa: Clear colourless liquid

Property	Value	Data Source/Justification
Melting Point	<-80 °C	Measured
Boiling Point	177 °C at 101.3 kPa	Measured
Density	922 kg/m 3 at 20 $^{\circ}$ C	Measured
Vapour Pressure	0.21 kPa at 25 °C	Measured
Water Solubility	$> 1 \times 10^3$ g/L at 20 °C	Measured
Hydrolysis as a Function of pH	$t_{\frac{1}{2}} > 1$ year at 25 °C at pH 4 – 9	Measured
Partition Coefficient	$\log Pow = -0.1$ at 20 °C	Measured
(n-octanol/water)		
Adsorption/Desorption	$\log K_{\rm oc} < 1.26$	Measured
Dissociation Constant	Not determined	Does not contain dissociable
		functionalities
Flash Point (closed cup)	69 °C at 101.8 kPa	Measured
Flammability Limits	Lower limit: 2.5% volume.	MSDS
	Upper limit: 33.0% volume	
Autoignition Temperature	175 °C	Measured
Explosive Properties	Not explosive	Contains no chemical groups associated
		with explosive properties.
Oxidising Properties	Not determined	Contains no functional groups that would
		imply oxidative properties

DISCUSSION OF PROPERTIES

For full details of tests on physical and chemical properties, refer to Appendix A.

Reactivity

The notified chemical is expected to be stable under normal conditions of use.

Physical hazard classification

Based on the submitted physico-chemical data depicted in the above table, the notified chemical is recommended for hazard classification according to the *Globally Harmonised System of Classification and Labelling of Chemicals (GHS)*, as adopted for industrial chemicals in Australia. The recommended hazard classification is presented in the following table.

Hazard classification	Hazard statement
Flammable Liquids Category 4	H227 – Combustible liquid

5. INTRODUCTION AND USE INFORMATION

MODE OF INTRODUCTION OF NOTIFIED CHEMICAL (100%) OVER NEXT 5 YEARS

The notified chemical will not be manufactured in Australia. The notified chemical will be imported as a component (10 - 25% concentration) of inks for wide format ink-jet printers in sealed cartridges (maximum capacity of 700 mL). The neat form of the notified chemical will not be imported.

MAXIMUM INTRODUCTION VOLUME OF NOTIFIED CHEMICAL (100%) OVER NEXT 5 YEARS

Year	1	2	3	4	5
Tonnes	0.7	1.5	3	4	5

PORT OF ENTRY

Sydney

IDENTITY OF MANUFACTURER/RECIPIENTS

The ink cartridges will be received in Australia by Epson Australia Pty Ltd.

TRANSPORTATION AND PACKAGING

The sealed ink cartridges containing the notified chemical will be transported by road throughout Australia.

USE

The notified chemical is a solvent in inks for wide format ink-jet printers for industrial and commercial use, and will be used at 10 - 25% concentration.

OPERATION DESCRIPTION

No reformulation or repackaging of the notified chemical will occur in Australia.

The cartridges containing the notified chemical at 10 - 25% concentration will be delivered to the end-user printing sites in the same packaging in which they are imported. Typical substrates that will be printed include posters, signboards and billboards. The sealed cartridges containing maximum 700 mL of ink will be handled by service technicians or workers in accordance with the instructions provided with the packages. Up to ten cartridges may be installed in each printer. Cleaning cartridges with a capacity of 350 mL, also containing the notified chemical, may be used by the service technicians and workers to clean the printing heads during maintenance. Workers will also carry out adjustments to the machines, including manual cleaning processes.

During printing, the ink containing the notified chemical will be transferred from the cartridges to the printing heads. The printing processes are expected to be fully automated, and the printers will have heaters as part of the equipment. During and immediately after the printing process, much of the notified chemical is expected to be volatilised. Small proportions of the chemical may be trapped in the printing substrates and volatilise slowly after printing.

6. HUMAN HEALTH IMPLICATIONS

6.1. Exposure Assessment

6.1.1. Occupational Exposure

EXPOSURE DETAILS

Transport and storage

Transport and storage workers are unlikely to be exposed to the notified chemical except in the event of an accidental cartridge rupture.

End-use

Under the proposed use scenario, print workers and service technicians may have the potential for dermal and ocular exposure to the inks containing the notified chemical at 10 - 25% concentration during ink cartridge replacement and printer maintenance and cleaning. As the ink cartridges are purposely designed to enclose the ink, and the printing processes are automated, the potential for dermal and ocular exposure to the notified chemical during printing is expected to be limited. Workers handling articles before the inks have completely dried may also come into minor dermal contact with the notified chemical in liquid form up to 25% concentration. The notifier stated that, if dermal exposure to the inks containing the notified chemical is likely to occur, service technicians and print workers are required to wear protective gloves to minimise the potential for exposure.

Repeated inhalation exposure of workers to the notified chemical may occur during and after the printing process, as a large proportion of the chemical is expected to be volatilised during printing. Further vapour may be released slowly from the print matrix, contributing to worker inhalation exposure in the printing and print article storage areas. Specific engineering controls or respiratory personal protective equipment (PPE) to reduce inhalation exposure have not been proposed by the notifier.

In a typical use scenario provided by the notifier, assuming an average office air space of 180 m³ with an airflow rate of 2.2 changes/hour and with one printer carrying 10 ink cartridges operating in the office, the average air concentration of the notified chemical may reach 17 mg/m³, if each ink cartridge is expected to be used for 30 days. Workers with an average body weight of 60 kg, assumed air inhalation rate of 23 m³/day and exposure for 8 hours a day may inhale the notified chemical in a level of 2.17 mg/kg bw/day. It is acknowledged that there is a paucity of relevant exposure data for workers and that variables such as workshop dimensions and number of printers per site highly influence the estimated dose. The pattern of worker exposure is also highly variable and uncertain. For example, workers working in proximity of the printers while the printing processes are still occurring may be exposed to significantly higher than average level of the notified chemical, if local exhaust ventilation above the printing head is absent or insufficient.

Once the inks are dried, the notified chemical is expected to have evaporated and will not be available for further exposure.

6.1.2. Public Exposure

The ink cartridges containing the notified chemical at 10 - 25% concentration are intended for use in industrial and commercial settings and will not be sold to the public. The public may come into contact with dried inks after application to the substrates. However, once the inks are dried, the notified chemical is expected to be evaporated and will not be available for exposure to the public.

6.2. Human Health Effects Assessment

The results from toxicological investigations conducted on the notified chemical are summarised in the following table. For full details of the studies, refer to Appendix B.

Endpoint	Result and Assessment Conclusion
Rat, acute oral toxicity	LD50 > 2,000 mg/kg bw; low toxicity
Rat, acute dermal toxicity	LD50 > 2,000 mg/kg bw; low toxicity
Rabbit, skin irritation (2 studies)	Non-irritating to slightly irritating
Rabbit, eye irritation	Slightly irritating
Guinea pig, skin sensitisation – non-adjuvant test	No evidence of sensitisation

Rat, repeat dose oral toxicity -28 days* NOAEL = 250 mg/kg bw/day

Rat, repeat dose oral toxicity combined with reproductive/developmental toxicity screening – 42 days dose and reproductive/developmental toxicity

Mutagenicity – bacterial reverse mutation (2 studies)

Genotoxicity – simplified *in vitro* mammalian chromosome

Non genotoxic

aberration

Genotoxicity – *in vitro* mammalian chromosome aberration Non genotoxic Genotoxicity – *in vivo* mammalian micronucleus test Non genotoxic

Toxicokinetics, metabolism and distribution

The notified chemical has a molecular weight < 500 and is highly water soluble. Based on its chemical and physical characteristics and information on the similar chemical diethylene glycol dimethyl ether (CAS 111-96-6), it is expected that the notified chemical would be readily absorbed through biomembranes via all routes, distributed within the body and metabolised. It has been reported that dermal absorption of glycol ethers in both liquid and vapour form is very high (CICAD, 2002).

Acute toxicity

Acute toxicity studies on the notified chemical suggested that the chemical is of low toxicity via the oral and dermal routes with LD50 > 2,000 mg/kg bw. Although no mortality at the dose level of 2,000 mg/kg bw in the oral toxicity study was observed, clinical signs such as dorsal positions and inanimation were recorded in the test animals for the first day following the oral administration.

No acute inhalation toxicity information was provided for the notified chemical.

Irritation and sensitisation

Two skin irritation studies in rabbit were provided for the notified chemical. One of the studies showed no skin irritation properties for the notified chemical while the other showed reversible skin irritation scores below the GHS classification criteria. Based on the results, the notified chemical is likely to be slightly irritating to the skin.

An eye irritation study on the notified chemical showed that the chemical is slightly irritating to the eye with reversible effects.

A Buehler test on the notified chemical in guinea pigs did not reveal evidence of reactions indicative of skin sensitisation.

Repeated dose toxicity

Two repeated dose oral toxicity studies were made available for the notified chemical. A 42-day combined repeated dose oral toxicity study on the notified chemical with reproductive/developmental toxicity screening test was submitted by the notifier (Mitsubishi, 2014a). In this study, the dose levels were selected as 50, 250 and 1,000 mg/kg bw/day based on a 14-day range finding study. Two recovery groups, administered at 0 or 1,000 mg/kg bw/day, were also included in the study for a recovery period of 2 weeks.

A 28-day repeated dose toxicity study on the notified chemical conducted to OECD TG 407 was also available. Details of the study were included in the NICNAS assessment report STD/1541 published on the NICNAS website. Dose levels tested in this study were 250, 500 and 1,000 mg/kg bw/day. Two recovery groups (for a recovery period of 2 weeks) were administered at 0 or 1,000 mg/kg bw/day.

Both studies used a Sprague-Dawley strain of rat, with animals dosed by gavage. Combined, the 42-day and 28-day studies provide data for a dose response characterisation with dose levels of 0, 50, 250, 500 and 1,000 mg/kg bw/day. Additionally, a direct comparison can be made between the studies at 250 and 1,000 mg/kg bw/day and at 1,000 mg/kg bw/day following a 2 week recovery period.

Mortality

In the 42-day repeated dose oral toxicity study combined with reproductive/developmental screening test, no deaths occurred during the 6-week dosing period, including the highest dose level of 1,000 mg/kg bw/day. In the 28-day repeated dose oral toxicity study, at the dose level of 1,000 mg/kg bw/day, 2 of 10 males were found dead during the dosing period. The cause of deaths was not established by histopathology examination. The

^{*} Details of the study are available in the NICNAS assessment report STD/1541 published on the NICNAS website.

clinical sign seen in these 2 animals was limited to a decrease in spontaneous motor activity on Day 9 only. An absence of treatment-related clinical signs of toxicity and effects on body weight in the animals of both studies, and the fact that no deaths were seen in the 42-day study suggest that the deaths in the 28-day study were unlikely to be related to the test material.

Clinical observations

Behavioural findings were not observed in the 42-day study. In the 28-day study, at dose levels of 500 or 1,000 mg/kg bw/day, the notified chemical induced a few sporadic behavioural changes in males during the treatment. Thus, an evaluation of all the available data does not provide robust evidence of treatment-related clinical signs of toxicity or a neurotoxicity potential for the notified chemical.

No treatment-related effect was seen on body weight or food consumption in either of the two available repeated dose studies up to the dose level of 1,000 mg/kg bw/day, including recovery groups.

Laboratory findings

Statistically significant decreases were seen in alkaline phosphatase, sodium and chloride in both the 42-day and 28-day studies at 1,000 mg/kg bw/day. The alkaline phosphatase changes were also seen in the 28-day study at the dose levels of 250 and 500 mg/kg bw/day, and may possibly be reflective of an adverse effect on metabolic function. These changes were considered to be treatment-related and potentially toxicologically significant at 500 and 1,000 mg/kg bw/day. The decreases in sodium and chloride were slight and absent in animals at the end of recovery period. Therefore, these findings are not considered toxicologically significant but potentially treatment-related. No treatment-related toxicologically significant changes in clinical chemistry parameters occurred at the next dose level of 250 mg/kg bw/day in either the 42-day or the 28-day study.

In the 42-day study, statistically significant changes were seen at 1,000 mg/kg bw/day: decrease in mean corpuscular haemoglobin concentration, eosinophil count and ratio, and increase in monocyte ratio. In the 28-day study, statistically significant changes were seen in haematology parameters: reduction in haemoglobin concentration and reticulocyte count at 500 and 1,000 mg/kg bw/day, and increase in monocytes at 1,000 mg/kg bw/day. An evaluation of all the available data therefore provides robust evidence of a treatment-related and toxicologically significant increase in monocytes, eosinophils and eosinophil ratio at 1,000 mg/kg bw/day. No treatment-related toxicologically significant changes in haematology parameters were considered to occur at the next dose level of 500 mg/kg bw/day.

No treatment-related effect was seen on urinalysis parameters in either study, up to the highest dose level of 1,000 mg/kg bw/day, including the recovery groups.

Effects on non-reproductive organs

In the 42-day study, statistically significant changes in liver (increase) and thymus (decrease) weight were reported at the dose level of 1,000 mg/kg bw/day. In the 28-day study changes in spleen and liver (increase), adrenal and thymus (decrease) weight were consistently seen at the dose level of 1,000 mg/kg bw/day. Liver weight increase was also seen in animals treated at 500 mg/kg bw/day. While the liver weight changes were associated with microscopic changes, the thymus weight changes were associated with macroscopic and microscopic changes. The liver and thymus weight changes are considered potentially treatment-related and toxicologically significant. The adrenal weight findings in the 28-day study were seen in the absence of macroscopic and microscopic changes and are not considered toxicologically significant. The spleen weight findings in the 28-day study were seen in the presence of macroscopic and microscopic changes, but the findings were absent in the 42-day study, suggesting that the findings were likely not related to the test material. No treatment-related toxicologically significant changes in organ weights were considered to occur at the next dose level of 250 mg/kg bw/day.

The limited finding of minimal periacinar hepatocyte hypertrophy in the liver of 1 animal of the recovery group administered at 1,000 mg/kg bw/day in the 28-day study was not seen in the 42-day study. Thus, it is not considered to be toxicologically significant but it may potentially be treatment-related.

At the end of the recovery period, no adverse treatment effects on the non-reproductive organs were seen in males administered at 1,000 mg/kg bw/day.

Reproductive/developmental toxicity

Reproductive toxicity

In both the 42-day and 28-day studies, reproductive/developmental toxicity-related findings were observed in the high dose treatment group of 1,000 mg/kg bw/day. Statistically significant reductions in epididymis and testis weights of the males were associated with histopathological changes in the reproductive organs including degeneration/necrosis of spermatocyte/spermatid, decrease of sperm and appearance of cell debris in the duct of the epididymides, some of which were of increased degree and incidence at the end of the recovery period. Reversibility of organ weight reductions was not recorded in either study, following a 2 week recovery period. These changes are considered treatment-related and toxicologically significant.

No treatment-related macroscopic effect was seen on male sex organs in either study at the end of the dosing period or at the end of the recovery period, up to and including 1,000 mg/kg bw/day.

Sperm analysis was carried out in the 28-day study at the end of the dosing period. The following effects seen in males administered at 1,000 mg/kg bw/day were considered treatment-related and toxicologically significant:

- Motility and count: a decrease in motility of spermatozoa and an increase in immobile spermatozoa which were associated with a decrease in percentage mobile spermatozoa.
- Morphology: a statistically significant (p < 0.05) decrease in the percentage of normal spermatozoa and a statistically significant (p < 0.05) increase in percentage spermatozoa with head anomaly which were associated with an increase (not statistically significant) in percentage of isolated head in the sample.
- Numeration in epididymis: a statistically significant (p < 0.01) lower epididymis tail weight and a decrease (not statistically significant) in the number of spermatozoa in the tail of the left epididymis.

Overall, a comparison of the data between the two available studies shows no significant qualitative differences in effects on male reproductive organs of the test material. Both studies provide no evidence of treatment-related macroscopic changes in male sex organs. However, both studies demonstrated a reduction in testis and epididymis weight along with microscopic changes in these organs at the dose level of 1,000 mg/kg bw/day. Additionally, in the study where sperm analysis was carried out, toxicologically significant changes were seen.

There were no effects of reproductive toxicity seen at the next dose levels of 250 or 500 mg/kg bw/day in the 42-day or the 28-day study, respectively.

Developmental toxicity

In the 42-day study, combined with reproductive/developmental toxicity screening test, prolongation of gestation period and decrease of delivery index were noted in females treated at the dose level of 1,000 mg/kg bw/day. In offspring, a decrease of litter number and birth index, and increase of number of stillborn were observed that were significantly different from the parameters of the vehicle control. Other adverse effects seen in the high dose group were total litter loss in 5 females and at post-natal Day 4 a reduced viability index and low body weights of offspring. The No Observed Adverse Effect Level (NOAEL) was established as 250 mg/kg bw/day in this study for both the repeated dose toxicity and the reproductive/developmental toxicity, based on the effects observed at the dose level of 1,000 mg/kg bw/day.

Further considerations

Based on the evaluation of the two available studies, it can be concluded that the observed findings in male reproductive organs at the dose level of 1,000 mg/kg bw/day cannot be considered as a secondary, non-specific consequence of other toxic effects. The observed deaths in the 28-day study, sporadic clinical signs, limited changes in haematology parameters, change in a single clinical chemistry parameter, organ weight changes in the liver and thymus, macroscopic changes in the thymus, and microscopic changes in the liver and thymus, are not considered to provide evidence of significant generalized toxicity for which the observed findings in male reproductive organs can be considered as secondary, non-specific consequence.

The 42-day study provided by the notifier produced the same findings as in the 28-day study regarding the male reproductive organs at the dose level of 1,000 mg/kg bw/day, such as decreases in absolute and relative testis and epididymis weight and microscopic changes in these organs. These effects on the male reproductive organs in both studies did not reverse after a 2 week recovery period and were consistent with the

reproductive/developmental hazards seen with some other short chain glycol ethers of this chemical class. Therefore, the concern that the notified chemical is a potential hazard for reproductive toxicity cannot be currently dismissed based on the available data. Additionally, this concern is supported by the fact that certain glycol ethers of this chemical class are considered as reproductive toxicants. *Safe Work Australia* (SWA) has listed a structurally very similar chemical, diethylene glycol dimethyl ether (CAS No. 111-96-6), as a reproductive Category 2 toxicant in the *Hazardous Substances Information System* (HSIS, web link - http://hsis.safeworkaustralia.gov.au/).

Recently, the US EPA has issued a Significant New Use Rule (SNUR, US EPA, 2014) on 7 commercially available ethylene glycol ethers regarding reproductive hazard concerns for this group of chemicals. According to the US EPA, based on both toxicity data and structure-activity relationships, ethylene glycol ethers that consist of 1, 2 or 3 glycol ether groups and terminal alkyl groups of 1 to 4 carbons can be anticipated to cause developmental and reproductive toxicity and/or haemolytic toxicity. Based on the structure of the notified chemical, it characteristically falls into the same category of ethylene glycol ethers for which the US EPA raised concerns. According to the US EPA SNUR documents, ethylene glycol ethers have been shown to cause damage to reproductive organs as well as toxicity to blood and blood forming organs. Exposure to this group of chemicals can pose risks to consumers, workers and children because of potential birth defects due to damage of reproductive organs.

Mutagenicity/Genotoxicity

The notified chemical is not expected to be mutagenic or genotoxic, as two bacterial reverse mutation assays and two *in vitro* mammalian chromosome aberration tests did not reveal evidence of genotoxicity. One *in vivo* mammalian erythrocyte micronucleus test also did not show evidence of clastogenicity for the notified chemical. However, as no clinical effects of toxicity were observed during the study, evidence of the test substance reaching bone marrow to produce clastogenicity could not be verified. Overall, based on the information available there is not a strong concern for genotoxicity.

Health hazard classification

Evaluation of the 42-day repeated dose toxicity study provided by the notifier concluded that the observed findings in male reproductive organs at 1,000 mg/kg bw/day were toxicologically significant and not considered a secondary non-specific consequence of other toxic effects. The study also raised concerns for developmental toxicity at the highest dose tested of 1,000 mg/kg bw/day. According to the GHS (Section 3.7.2.5.3), findings on male reproductive organs in repeat dose studies can be considered sufficient to justify classification for reproductive toxicity in the absence of a one or two generation test.

The systemic findings in the 28-day repeated dose toxicity study, excluding effects on the male reproductive organs, are also not considered to constitute marked toxicity of the test substance such that the observed effects on male reproductive organs may be considered a secondary, non-specific consequence of such. Supportive evidence includes observed deaths at 1,000 mg/kg bw/day being unlikely to be related to the test material; no significant changes in bodyweight and food consumption; sporadic clinical signs of toxicity; limited (and generally non-reproducible) changes in haematology parameters; change in a single clinical chemistry parameter; and limited macroscopic changes and changes to organ weight. Furthermore, there were observed changes in male reproductive organs, including histopathological changes, which were still evident after a 2 week recovery period.

The 42-day and 28-day studies produced the same findings at 1,000 mg/kg bw/day: decreases in absolute and relative (to bw) testis and epididymis weight, and microscopic changes in these organs. Both studies also showed no reversibility of effects on testis and epididymis weight and microscopic changes in these organs after a 2-week recovery period. Additionally, sperm analysis in the epididymis was undertaken in the 28-day study with treatment-related effects being noted on motility, count, morphology and numeration in the epididymis at 1,000 mg/kg bw/day.

Overall, based on the findings observed in the two repeated dose studies, which are not considered as a secondary non-specific consequence of other toxic effects, it is concluded that the full safety of the notified chemical has not currently been established, with respect to reproduction and development. Classification as a Category 2 reproductive toxicant under the GHS is therefore justified in this instance, for the notified chemical.

Based on the available information, the notified chemical is recommended for classification according to the Globally Harmonised System of Classification and Labelling of Chemicals (GHS), as adopted for industrial chemicals in Australia. The recommended hazard classification is presented in the table below.

Hazard classification	Hazard statement
Reproductive Toxicity Category 2	H361 – Suspected of damaging fertility or the unborn child.
Suspected Human Reproductive Toxicant	

Based on the available information, the notified chemical is recommended for hazard classification according to the *Approved Criteria for Classifying Hazardous Substances* (NOHSC, 2004), with the following risk phrases:

R62/63: Possible risk of impaired fertility/Possible risk of harm to the unborn child

6.3. Human Health Risk Characterisation

6.3.1. Occupational Health and Safety

According to the study reports provided, the notified chemical may be slightly irritating to the skin and eye. However, the enclosed nature of the packaging containing the notified chemical at a concentration $\leq 25\%$ and the provision of handling instructions would limit the irritation effects and dermal/ocular exposure. Dermal exposure could also occur to vapour released during and after printing. The notifier stated in the submission that, if dermal exposure to the inks containing the notified chemical is likely to occur, service technicians and workers are required to wear protective gloves to minimise the potential for exposure.

The major concern for long-term exposure to the notified chemical is the possibility of adverse reproductive and/or developmental outcomes to workers carrying out printing and associated processes. As the notified chemical is expected to volatilise during printing and drying, inhalation exposure to workers during and after printing is expected to be the largest contributor to systemic exposure. Based on the NOAEL of 250 mg/kg bw/day established in the repeated oral toxicity study combined with reproductive/developmental toxicity screening for the notified chemical and the daily average inhalation uptake of 2.17 mg/kg bw/day in a typical use scenario (see Section 6.1.1), a margin of exposure (MoE) can then be calculated as approximately 115. A MoE value ≥ 100 is considered to be acceptable for the proposed use scenario. However, as mentioned in Section 6.1.1, there is a paucity of relevant exposure data for workers. The worker inhalation exposure scenario is also uncertain. It is acknowledged that these factors highly influence the calculated MoE. Therefore, given the hazard profile of the notified chemical, risk controls (i.e., engineering, work practices and PPE) should be implemented and their effectiveness monitored.

Under the conditions of use provided by the notifier regarding the product composition, usage and scenarios of use, the risk to printing workers from the use of the notified chemical is not expected to be unreasonable. However changes in use parameters such as higher usage of the ink containing the notified chemical, higher concentrations of the notified chemical in the inks, or printing in poorly ventilated or small areas may increase the inhalation exposure and thus the risk. Therefore controls to reduce inhalation exposure during printing and while the printed media are drying would further reduce exposure and risk. These could include enhanced ventilation controls and safe work practices. The Safe Work Australia (SWA) guidance document, *P39 –Wide-format inkjet printing with solvent-borne inks*, recommends providing a good standard of general ventilation, and that ventilation equipment is maintained and working effectively. In order to provide the fresh air, powered wall-or window-mounted fans, with five to ten air changes per hour and a through draught, are recommended in this guidance document that is higher than the expected ventilation under the scenario provided by the notifier. Safe work practices and use of appropriate PPE would further reduce exposure. The notifier has advised that gloves will be worn if contact with the liquid ink is expected.

While the notified chemical is classified as a flammable liquid Class 4, under the proposed use scenario it is not likely that the air concentration of the notified chemical would reach the lower explosion limit of 2.5% if effective engineering controls (ventilation) are in place to reduce the inhalation exposure of workers. Therefore, if these controls are in place, the notified chemical is not expected to pose a flammability hazard in the workplace.

Provided that adequate workplace controls are in place to reduce exposure to the inks containing the notified chemical, the risk to workers is not considered unreasonable.

6.3.2. Public Health

The products containing the notified chemical will not be sold to the public. The public may have contact with dry printed materials. However, as the notified chemical is used as a solvent of the ink, it is expected to be

evaporated during the printing and not to be available for exposure after drying. Therefore, based on the use scenario, the risk of the notified chemical to the health of the public is not considered to be unreasonable.

7. ENVIRONMENTAL IMPLICATIONS

7.1. Environmental Exposure & Fate Assessment

7.1.1. Environmental Exposure

RELEASE OF CHEMICAL AT SITE

The notified chemical will not be manufactured or reformulated in Australia. It will be imported in sealed cartridges. The ink cartridges are designed to prevent leakage and will not be opened during transport. Therefore there will be no release of the notified chemical to the environment from these activities.

RELEASE OF CHEMICAL FROM USE

The ink cartridges are designed to prevent leakage and will not be opened during use, installation or replacement. Therefore there will be no release of the notified chemical to the environment from these activities under normal conditions. However, if leakage or spillage occurs, the ink containing the notified chemical is expected to be contained with absorbent materials and sent to licensed waste disposal contractors. The residual ink containing the notified chemical (2% of the total import volume) is expected to be disposed of to landfill. The majority of the notified chemical is expected to be evaporated during the printing process.

RELEASE OF CHEMICAL FROM DISPOSAL

Empty cartridges containing the notified chemical are expected to be disposed of to landfill.

7.1.2. Environmental Fate

As the majority of the notified chemical is expected to be released to the atmosphere, the potential for the notified chemical to persist and experience long range transport was assessed (AOP Program v1.92; US EPA, 2011). The notified chemical is predicted to experience a half-life of 3.7 hours (assuming a 12 hour day). As such, it is expected that the notified chemical will undergo rapid degradation via reactions with OH-radicals, and will not experience long-range transport.

The notified chemical trapped in the ink matrices is expected to be disposed of to landfill with the substrate to which the ink is applied. The notified chemical is not readily biodegradable. Given the high water solubility and low log Koc, the notified chemical may leach from landfill and enter surface waters. A small proportion of the notified chemical may be released to sewer during paper recycling. Given the high water solubility and low log Koc, the notified chemical is not expected to partition to sludge during waste water treatment processes in sewage treatment plants (STPs). Therefore, the notified chemical is expected to remain in waste water and be released to aquatic environments.

Based on its high water solubility and low log Pow, the notified chemical is not expected to bioaccumulate. Ultimately, the notified chemical is expected to degrade via biotic and abiotic processes in the atmosphere and surface waters to form water and oxides of carbon.

7.1.3. Predicted Environmental Concentration (PEC)

Based on its use in printing, it is conservatively assumed that 100% of the total import volume of the notified chemical was used in paper printing. Using a worst-case scenario, it is assumed that 50% of the paper products containing the notified chemical will be recycled and will be released to the sewer with no removal during recycling or STP processes. As the notified chemical is to be processed at paper recycling facilities located throughout Australia, it is anticipated that such releases will occur on 260 days into the Australian effluent volume. The resultant estimate for the predicted environmental concentration (PEC) in sewage effluent nationwide is summarised in the table below.

Predicted Environmental Concentration (PEC) for the Aquatic Compartment				
Total Annual Import/Manufactured Volume	5,000	kg/year		
Proportion expected to be released to sewer	50%			
Annual quantity of chemical released to sewer	2,500	kg/year		
Days per year where release occurs	260	days/year		
Daily chemical release:	9.62	kg/day		

Water use	200.0	L/person/day
Population of Australia (Millions)	22.613	million
Removal within STP	0%	
Daily effluent production:	4,523	ML
Dilution Factor - River	1.0	
Dilution Factor - Ocean	10.0	
PEC - River:	2.13	μg/L
PEC - Ocean:	0.21	μg/L

STP effluent re-use for irrigation occurs throughout Australia. The agricultural irrigation application rate is assumed to be 1,000 L/m²/year (10 ML/ha/year). The notified chemical in this volume is assumed to infiltrate and accumulate in the top 10 cm of soil (density 1500 kg/m³). Using these assumptions, irrigation with a concentration of 2.1 μ g/L may potentially result in a soil concentration of approximately 14.2 μ g/kg from each year of irrigation. Assuming accumulation of the notified chemical in soil for 5 and 10 years under repeated irrigation, the concentration of notified chemical in the applied soil in 5 and 10 years may be approximately 70.9 μ g/kg and 141.7 μ g/kg, respectively.

7.2. Environmental Effects Assessment

Ecotoxicological data were submitted for the notified chemical. Details of the studies can be found in Appendix C.

Endpoint	Result	Assessment Conclusion
Fish	LC50 (96 h) > 90.8 mg/L	Not harmful to fish at the tested concentration
Daphnia	LC50 (48 h) > 93.6 mg/L	Not harmful to aquatic invertebrates at the tested concentration
Algae	EC50 (96 h) > 89.5 mg/L	Not harmful to algae at the tested concentration

The notified chemical is not harmful to fish, aquatic invertebrates and algae at the tested concentrations. Therefore, under the *Globally Harmonised System of Classification and Labelling of Chemicals* (GHS; United Nations, 2009), the notified chemical has not been formally classified for acute and chronic toxicities.

7.2.1. Predicted No-Effect Concentration

The predicted no-effect concentration (PNEC) for the notified chemical has been calculated and is presented in the table below. The PNEC is calculated based on the endpoint for the most sensitive species (Algae, E_rC50) for the notified chemical. Acute ecotoxicity endpoints for aquatic species from three trophic levels are available. Therefore, an assessment factor of 100 has been used.

Predicted No-Effect Concentration (PNEC) for the Aquatic Compartment		
Endpoint (Lower Limit)	89.5	mg/L
Assessment Factor	100	
PNEC:	895.0	μg/L

7.3. Environmental Risk Assessment

The Risk Quotient values have been calculated as follows:

Risk□Assessment	PEC μg/L	PNEC μg/L	Q
Q - River	2.13	895	0.002
Q - Ocean	0.21	895	0.0002

The Risk Quotients (Q = PEC/PNEC) for a conservative discharge scenario have been calculated to be << 1 for the river and ocean compartments. The notified chemical is not expected to be bioaccumulative and is expected to slowly degrade in the environment. Based on the short half-life of the notified chemical in air, it is not expected to pose an unacceptable risk in this compartment. Based on the assumed low hazard and the assessed use pattern of the notified chemical, it is not expected to pose an unreasonable risk to the environment.

APPENDIX A: PHYSICAL AND CHEMICAL PROPERTIES

Melting Point <-80 °C

Method OECD TG 102 Melting Point/Melting Range.

EC Council Regulation No 440/2008 A.1 Melting/Freezing Temperature.

Remarks DSC method. No significant protocol deviations.

The chemical remained in liquid form at the lowest temperature tested (-80 °C).

Test Facility WIL Research (2014)

Boiling Point 177 °C at 101.3 kPa

Method OECD TG 103 Boiling Point.

EC Council Regulation No 440/2008 A.2 Boiling Temperature.

Remarks DSC method. No significant protocol deviations.

An endothermic peak below the boiling temperature was attributed to evaporation.

Test Facility WIL Research (2014)

Density $0.922 \times 10^{3} \text{ kg/m}^{3} \text{ at } 20 \text{ }^{\circ}\text{C}$

Method OECD TG 109 Density of Liquids and Solids.

EC Council Regulation No 440/2008 A.3 Relative Density.

Remarks Pycnometer method. No significant protocol deviations.

Test Facility WIL Research (2014)

Vapour Pressure 0.21 kPa at 25 °C

Method OECD TG 104 Vapour Pressure.

EC Council Regulation No 440/2008 A.4 Vapour Pressure.

Remarks Isothermal thermogravimetric effusion method. No significant protocol deviations.

Test Facility WIL Research (2014)

Solubility $> 1 \times 10^3 \text{ g/L at } 20 \text{ °C}$

Method OECD TG 105 Water Solubility

Remarks After the stirring period, the test substance was clear and no undissolved test substance was

observed. The solubility of the test substance was determined by visual observations.

Test Facility WIL Research (2014)

Hydrolysis as a Function of pH Hydrolytically stable

Method OECD TG 111 Hydrolysis as a Function of pH.

pH	T (°C)	$t_{1/2}$
4	25	> 1 year
7	25	> 1 year
9	25	> 1 year

Remarks The mean concentration of the test substance after 5 days at 50 °C had not decreased by

more than 10%. The test substance is considered hydrolytically stable according to the

criterion in data reporting guidelines for hydrolysis studies according to this test.

Test Facility WIL Research (2014)

Partition Coefficient (n-octanol/water) log Pow = -0.1 at 20 °C

Method OECD TG 107: Partition Coefficient (n-octanol/water), Shake Flask Method

Remarks The Shake flask method at neutral pH was applied for the determination of the partition

coefficient of the test substance.

Test Facility WIL Research (2014)

Adsorption/Desorption $\log K_{oc} < 1.26$

Method OECD TG 121 Adsorption – Estimation of the Adsorption Coefficient (Koc) on Soil and on

Sewage Sludge using High Performance Liquid Chromatography (HPLC).

Remarks The HPLC analysis was performed at neutral pH. The HPLC method using soil-adsorption-

reference data was applied for the determination of the adsorption coefficient (Koc) of the

test substance.

Test Facility WIL Research (2014)

Flash Point 69 °C at 101.8 kPa

Method EC Council Regulation No 440/2008 A.9 Flash Point.

Remarks Determined using the Pensky Martens Closed Cup method. No significant protocol

deviations.

Test Facility WIL Research (2014)

Autoignition Temperature 175 °C

Method EC Council Regulation No 440/2008 A.15 Auto-Ignition Temperature (Liquids and Gases).

Remarks No significant protocol deviations.

Test Facility WIL Research (2014)

Explosive Properties No explosive properties

Method EC Council Regulation No 440/2008 A.14 Explosive Properties.

Remarks The test substance does not contain chemical groups which are associated with explosive

properties.

Test Facility WIL Research (2014)

APPENDIX B: TOXICOLOGICAL INVESTIGATIONS

B.1. Acute toxicity – oral

TEST SUBSTANCE Notified chemical (99.98% in purity)

METHOD OECD TG 423 Acute Oral Toxicity – Acute Toxic Class Method

Species/Strain Rat/Crl:CD (SD), females
Vehicle Sterile distilled water

Remarks - Method No significant deviations of the protocol were noted.

RESULTS

Group	Number and Sex of Animals	Dose (mg/kg bw)	Mortality
1	3 (F)	2,000	0/3
2	3 (F)	2,000	0/3
LD50 Signs of Toxicity	as dorsal position	ow ons from 1 to 4 hours after dosi ons and inanimation were observ og bw. The signs were rec	ved in all test animals dosed
Effects in Organs	No necropsy finwere noted.	ndings caused by the administr	ration of the test substance
Remarks - Results	No mortality of	the test animals was noted during	ng the study.
CONCLUSION	The notified che	emical is of low toxicity via the	oral route.

TEST FACILITY KTR (2013a)

B.2. Acute toxicity – dermal

TEST SUBSTANCE Notified chemical (99.98% in purity)

METHOD OECD TG 402 Acute Dermal Toxicity (Limit Test)

Species/Strain Rat/Crl:CD (SD), SPF
Vehicle Sterile distilled water
Type of dressing Semi-occlusive

Remarks - Method No significant deviations of the protocol were noted. A control group was

included.

RESULTS

Group	Number and Sex	Dose	Mortality
	of Animals	mg/kg bw	
1	10 (5 F/5 M)	0	0/10
2	10 (5 F/5 M)	2,000	0/10

LD50 > 2,000 mg/kg bw

Signs of Toxicity - Local No local clinical signs related to the administration of the test substance

were noted.

Signs of Toxicity - Systemic No systemic clinical signs related to the administration of the test

substance were noted.

Effects in Organs No necropsy findings related to the administrations of the test substance

were noted.

Remarks - Results No mortality of the test animals was noted during the study.

CONCLUSION The notified chemical is of low toxicity via the dermal route.

TEST FACILITY KTR (2013b)

B.3. Irritation – skin (1)

TEST SUBSTANCE Notified chemical

METHOD OECD TG 404 Acute Dermal Irritation/Corrosion

EC Directive 92/69/EEC B.4 Acute Toxicity (Skin Irritation)

Species/Strain Rabbit/New Zealand White

Number of Animals 3 Vehicle None

Observation Period 4 hours exposure, 7 days observation after removal of treatment

Type of Dressing Semi-occlusive

Remarks - Method The purity of the test substance was not specified.

After the 4 h application period, any residual test material was removed by

gentle swabbing with 74% industrial methylated spirits.

RESULTS

Lesion		Aean Scor Animal N	-	Maximum Value	Maximum Duration of Any Effect	Maximum Value at End of Observation Period
	1	2	3		•	·
Erythema/Eschar	2	1.7	1.3	2	< 7 days	0
Oedema	1	1	0.3	2	> 72 hours	0

^{*} Calculated on the basis of the scores at 24, 48, and 72 hours for EACH animal.

Remarks - Results Well defined erythema and slight oedema was noted at all treated skin sites

after 1 hour after the patch removal. After 7 days, the irritation effects were recovered; however, slight desquamation was observed on all treatment

sites.

CONCLUSION The notified chemical is slightly irritating to the skin.

TEST FACILITY Safepharm (1997a)

B.4. Irritation – skin (2)

TEST SUBSTANCE Notified chemical (99.98% in purity)

METHOD OECD TG 404 Acute Dermal Irritation/Corrosion

Species/Strain Rabbit/New Zealand White, females

Number of Animals 3 Vehicle None

Observation Period 4 hours exposure, 72 hours observation after removal of treatment

Type of Dressing Semi-occlusive

Remarks - Method No significant deviations of the protocol were noted. The animals were

treated sequentially, to check for any serious effects. Observations were

taken for 72 h after patch removal.

RESULTS

Remarks - Results No dermal irritation (including erythema/eschar and oedema) scores above

zero for the test substance were recorded in the study.

No test substance-related clinical signs and mortality were noted during the

study. Body weight gains were as expected.

CONCLUSION The notified chemical is non-irritating to the skin.

TEST FACILITY KTR (2014a)

B.5. Irritation – eye

TEST SUBSTANCE Notified chemical (99.98% in purity)

METHOD OECD TG 405 Acute Eye Irritation/Corrosion

Species/Strain Rabbit/New Zealand White

Number of Animals 3 (Females) Observation Period 6 days

Remarks - Method No significant deviations of the protocol were noted. Five minutes prior to

treatment, two drops of a topical ocular anaesthetic (0.5% proparacaine hydrochloride) were applied to each test eye. The test substance in the

amount of 0.1 mL per treatment was then applied.

RESULTS

Lesion		Mean Score* Animal No.		Maximum Value	Maximum Duration of Any Effect	Maximum Value at End of Observation Period
	1	2	3		V V	-
Conjunctiva: redness	1.67	1.67	1.67	2	< 6 days	0
Conjunctiva: chemosis	1	1	0.67	2	< 72 hours	0
Conjunctiva: discharge	0.33	1	0.33	2	< 72 hours	0
Corneal opacity	0	0	0	0	-	0
Iridial inflammation	0	0	0	0	-	0

^{*} Calculated on the basis of the scores at 24, 48, and 72 hours for EACH animal.

conjunctiva redness, discharge and chemosis were observed. These signs

were recovered within 6 days.

CONCLUSION The notified chemical is slightly irritating to the eye.

TEST FACILITY KTR (2014b)

B.6. Skin sensitisation

TEST SUBSTANCE Notified chemical (99.98% in purity)

METHOD OECD TG 406 Skin Sensitisation – Buehler Test Method

Species/Strain Guinea pig/ElmSam:HA, males

PRELIMINARY STUDY Maximum Non-irritating Concentration:

topical: 100%

MAIN STUDY

Number of Animals Test Group: 20 Control Groups: 10 positive/10 negative

INDUCTION PHASE Induction Concentration: topical: 100%

Inductions were applied on Days 0, 7 and 14 on the same induction area

for each test animal.

Signs of Irritation Not noted

CHALLENGE PHASE Challenge Concentration topical: 100%

Challenge was applied on Day 28 on a new challenge area for each test

animal.

Remarks - Method Sterile distilled water was used as a vehicle for the test substance and as a

negative control. DNCB (1-chloro-2,4-dinitrobenzene) at 1% in corn oil

was used as a positive control.

RESULTS

Animals	Challenge Concentration	Skin Reactions after Challenge			enge
		24 h		48 h	
	_	S.I.	F.I.	S.I.	F.I.
Test Group (with induction exposure)	100% (test substance)	0	0	0	0
Negative Control Group	100% (test substance)	0	0	0	0
Positive Control Group	1% (DNCB)	1.6	100	0.6	60

S.I: sensitisation index (mean score of skin reaction in the group)

F.I: frequency index (percentage of animals with skin reaction in the group)

Remarks - Results One animal in the treatment group in the main study was accidentally

injured 1 day after first induction and was euthanized. No treatment-related mortality or clinical signs were observed in any treated animals. A

normal increase in body weight was seen in all surviving animals.

No skin reactions were seen in treated or negative control animals. The positive controls behaved as expected, confirming the validity of the test

system.

CONCLUSION There was no evidence of reactions indicative of skin sensitisation to the

notified chemical under the conditions of the test.

TEST FACILITY KTR (2014c)

B.7. Repeat dose toxicity – 14 day range-finding

TEST SUBSTANCE Notified chemical

METHOD Range-finding study to select doses for combined repeated dose and

reproductive/developmental toxicity screening test (see Appendix B.8.)

Observations and examinations: clinical signs, body weight, food

consumption, haematology, blood chemistry, necropsy and organ weight

Species/Strain Rat/Crl:CD (SD)
Route of Administration Oral – gavage

Exposure Information Total exposure days: 14 days

Dose regimen: 7 days per week Post-exposure observation period: none

Vehicle Water

Remarks - Method The purity of the test substance was not specified. No GLP statement was

provided.

RESULTS

Group	Number and Sex of Animals	Dose (mg/kg bw/day)	Mortality
Control	10 (5 F/5 M)	0	0/10
Low dose	10 (5 F/5 M)	110	0/10
Mid dose	10 (5 F/5 M)	330	0/10
High dose	10 (5 F/5 M)	1,000	0/10

Mortality and Time to Death

No unscheduled deaths of test animals were recorded.

Clinical Observations

No test substance related abnormality was noted in the test animals.

Laboratory Findings – Clinical Chemistry, Haematology, Urinalysis

Low values of mean corpuscular haemoglobin concentration (MCHC) were noted in males treated at dose levels ≥ 330 mg/kg bw/day. Low values of platelets, reticulocyte ratio and reticulocytes were noted in males treated at

a dose level of 1,000 mg/kg bw/day.

Effects in Organs

Increase of liver weight was noted in males treated at 1,000 mg/kg bw/day. Decrease of ovaries weight was noted in females treated at 1,000 mg/kg bw/day.

Remarks - Results

Decrease of relative testes weight in males treated at 110 and 1,000 mg/kg bw/day was also noted but considered as incidental by the study authors due to the lack of dose-dependency.

CONCLUSION

A high dose level of 1,000 mg/kg bw/day for the test substance was selected for the subsequent combined repeat dose toxicity study with reproductive/developmental toxicity screening test (see Appendix B.8.)

TEST FACILITY Mitsubishi (2013)

B.8. Repeat dose toxicity – 42-day study, combined with reproductive/developmental toxicity screening

TEST SUBSTANCE Notified chemical (99.98% in purity)

METHOD OECD TG 422 Combined Repeated Dose Toxicity Study with the

Reproduction/Developmental Toxicity Screening Test

Species/Strain Rat/Crl:CD (SD)
Route of Administration Oral – gavage

Exposure Information Total exposure days: 42 days for males and satellite females (without

mating); until Day 4 of lactation for females

Dose regimen: 7 days per week

Post-exposure observation period: 14 days

Vehicle Water

Remarks - Method Each group consisted of 12 males and 12 females. Five satellite females

each were added to the high dose (1,000 mg/kg bw/day) group and the control group. Ten animals (5 males and 5 satellite females) from the high dose group were examined for recovery along with ten animals (5 males

and 5 satellite females) from the control group.

RESULTS

Group	Number and Sex of Animals	Dose (mg/kg bw/day)	Mortality
Control	19 (7 M/12 F)	0	2/19
Low dose	24 (12 M/12 F)	50	0/24
Mid dose	24 (12 M/12 F)	250	2/24
High dose	19 (7 M/12 F)	1000	7/19
Control recovery	10 (5 M/5 F)	0	0/10
High dose recovery	10 (5 M/5 F)	1000	0/10

Mortality and Time to Death

All male animals survived the test until scheduled necropsy.

One female each in the control group and the high dose group, and 2 females in the mid dose group were found non-pregnant after mating. One female in the high dose group was found non-copulated and 1 female in the control group was found non-delivering. Above animals were terminated before the study was completed.

Due to total litter loss, 5 more unscheduled sacrifices were recorded in the females of the high dose group.

Clinical Observations

Decreased motor activity was noted in females of the high dose group.

Body Weight and Food Consumption

No significant difference of body weight was noted in males and females between the vehicle control and test groups throughout the dosing and recovery period, including female gestation and lactation period.

No treatment-related changes of food consumption were noted in the study. High values of food consumption were noted in females of the high dose recovery group on Day 50; however, the changes were not considered to be treatment-related since these changes were noted only at one measurement time point and no significant difference was noted in the body weight on Day 50.

Laboratory Findings - Clinical Chemistry, Haematology, Urinalysis

Haematology findings in the high dose group at the end of dosing included low values of platelets, white blood cells, neutrophils, basophils and large unstained cells in females and low mean corpuscular haemoglobin concentration (MCHC) in males. Changes in high dose group males at the end of recovery included a reduction in mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH) and MCHC, but were not considered by the study authors to be treatment related.

Some changes in clinical chemistry parameters after dosing and after recovery were noted by the study authors but not considered to be treatment related.

Qualitative urinalysis parameters tested in males only did not differ from the controls.

Effects in Organs

At the end of dosing, significant increase of liver weight was noted in high dose females and males. Compared to the vehicle control group, the absolute and relative liver weight increases for the males in the group were 29.0% (p < 0.05) and 23.6% (p < 0.01) respectively. For the females, the absolute liver weight increase was 17.9% (p < 0.05); however, the relative liver weight increase of 12.5% was not statistically significant. Microscopic findings revealed associated minimal to mild hypertrophy of centrilobular hepatocyte. While no hypertrophy of hepatocyte was noted in the vehicle control, low dose (50 mg/kg bw/day) and mid dose (250 mg/kg bw/day) groups for both males and females, 3 of the 5 males in the high dose group were found to have minimal hepatocyte hypertrophy and 1 male was found to have mild hepatocyte hypertrophy. For females of the high dose group, 3 of the 5 animals were found to have minimal hepatocyte hypertrophy.

Significant decrease of epididymides weight was recorded in the males of the high dose group at the end of dosing. Compared to the vehicle control group, the absolute and relative epididymides weight decreases were 21.5% and 24.2% (both p < 0.01) respectively. The decreases in weights of epididymides were associated with microscopic findings including degeneration/necrosis of spermatocyte/spermatid, decrease of sperm and cell debris in the duct of the epididymis. In addition, significant reduction of relative thymus weights in males of the high dose group was also noted (p < 0.05).

At the end of the recovery period, relative liver weight of high dose males remained 12.27% higher than the vehicle control group (p < 0.05). For females of the high dose group, absolute and relative liver weights were not significantly different from the vehicle control after the recovery. Hepatocyte hypertrophy was not seen in the recovery animals.

The weights of epididymides and testes were statistically significantly reduced for the males of the high dose group after the recovery. Compared to the vehicle control group, the absolute and relative epididymides weight decreases were 31.3% and 29.6% (both p < 0.01) respectively. The absolute and relative testes weight decreases were 26.0% (p < 0.01) and 23.3% (p < 0.05) respectively.

Other organ weight changes in the high dose recovery group, including thyroid weight increase in females and heart weight increase in males, were considered by the study authors not to be treatment-related.

Reproductive/Developmental Effects

In male animals, the significant decreases in weights of epididymides and testes in the high dose group were associated with histopathological changes, both at the end of dosing and end of the recovery period. (Testes weight changes were statistically significant only after the recovery period). Microscopic findings included minimal to mild degeneration/necrosis of spermatocyte/spermatid, decrease of sperm and cell debris in the duct of the epididymis. The study authors noted that the degree and incidence of these changes were greater at the end of the recovery period than at the end of dosing. At the end of dosing, minimal spermatocyte/spermatid degeneration/necrosis was found in 2 of 5 males in the high dose group while mild spermatocyte/spermatid degeneration/necrosis was found in 1 of the 5 animals. After the recovery period, minimal spermatocyte/spermatid degeneration/necrosis was found in 3 of the 5 males in the high dose group while mild spermatocyte/spermatid degeneration/necrosis was found in 1 of the 5 animals. Similar situations were seen in

the examinations of the epididymis of the high dose group with decrease of sperm and appearance of cell debris in the duct. The study authors considered that the changes in the testes were suggestive of effects on the spermatocytes/spermatids and the changes in the epididymis suggested degeneration of the seminiferous epithelium.

In female animals, prolongation of gestation period and decrease of delivery index were noted in the high dose group, with delivery index of 79.5% comparing to 91.9% in the vehicle control. Decrease of litter number and birth index and increase of number of stillborn were observed in the offspring of high dose females, with birth index of 70.5% comparing to 90.0% and stillborn rate of 11.2% comparing to 1.8% in the vehicle control. Total litter loss in 5 females of the high dose group was recorded, mostly due to cannibalism and loss of suckling. At postnatal Day 4, the offspring in the high dose had a lower viability index and body weight. The total viability index in this group was 48.2%, significantly lower than 98.7% in the vehicle control (p < 0.01). The study authors noted that there were no changes indicating implantation failure, however there was a decrease in delivery index and an effect on the maintenance of pregnancy.

The study authors suggested that although the causes of the changes in offspring remain unclear, it is possible that the test substance may have affected the offspring via milk.

No effect of the test substance was noted on mating or conception, despite the abnormalities seen in the testis and epididymis in males of the high dose group. The study authors suggested that this may be related to the maturation time of the sperm, and it is likely that the test substance may affect reproductive function if administered for a longer period before mating to cover a full spermatogenesis cycle.

Remarks – Results

The study authors considered the main treatment related observations for repeated dose toxicity were changes in organ weights and histological changes, in liver, testes and epididymis. For reproductive toxicity, they considered the effects on dams and offspring to be the main treatment related observations.

CONCLUSION

The No Observed Adverse Effect Level (NOAEL) was established as 250 mg/kg bw/day in this study for both the repeated dose toxicity and the reproductive toxicity, based on the adverse effects observed at the dose level of 1,000 mg/kg bw/day.

TEST FACILITY Mitsubishi (2014a)

B.9. Genotoxicity – bacterial reverse mutation test (1)

TEST SUBSTANCE Notified chemical (99.98% in purity)

METHOD OECD TG 471 Bacterial Reverse Mutation Test

Pre-incubation method

Species/Strain S. typhimurium: TA1535, TA1537, TA98, TA100

E. coli: WP2uvrA

Metabolic Activation System S9 mix (commercial phenobarbital and 5,6-benzoflavone induced rat liver

homogenate)

Concentration Range in a) With metabolic activation: $313 - 5{,}000 \mu g/plate$ Main Test b) Without metabolic activation: $313 - 5{,}000 \mu g/plate$

Vehicle Water

Remarks - Method No significant deviations of the protocol were noted. Dosages for the main

test were chosen on the basis of the preliminary test.

Preliminary Test: 1 plate/dose Main Tests: 3 plates/dose

RESULTS

Metabolic	Test Substance Concentration (µg/plate) Resulting in:				
Activation	Cytotoxicity in Preliminary Test	Cytotoxicity in Main Test	Precipitation	Genotoxic Effect	
Absent Preliminary Test	> 5,000	-	> 5,000	Negative	

Main Test I	_	> 5,000	> 5.000	Negative
Main Test II	-	> 5,000	> 5,000	Negative
Present				_
Preliminary Test	> 5,000	-	> 5,000	Negative
Main Test I	-	> 5,000	> 5,000	Negative
Main Test II	-	> 5,000	> 5,000	Negative

Remarks - Results Cytotoxicity and precipitation of the test substance were not observed with

or without metabolic activation during the study.

CONCLUSION The notified chemical was not mutagenic to bacteria under the conditions

of the test.

TEST FACILITY Japan Oilstuff Inspectors' Corporation (2013a)

B.10. Genotoxicity – bacterial reverse mutation test (2)

TEST SUBSTANCE Notified chemical

METHOD Similar to OECD TG 471 Bacterial Reverse Mutation Test

Plate incorporation procedure

Species/Strain S. typhimurium: TA1535, TA1537, TA98, TA100

E. coli: WP2uvrA-

Metabolic Activation System S9 mix (microsomal enzyme fraction of Aroclor 1254 induced rat liver

homogenate)

Concentration Range in a) With metabolic activation: $50 - 5,000 \mu g/plate$

Main Test b) Without metabolic activation: 50 – 5,000 μg/plate

Vehicle Water

Remarks - Method The purity of the test substance was not specified. Preliminary toxicity

study was conducted on TA100 and WP2uvrA- without metabolic

activation with test substance in the range of 50 to 5,000 µg/plate.

RESULTS

Metabolic	Test Substance Concentration (µg/plate) Resulting in:					
Activation	Cytotoxicity in	Cytotoxicity in	Precipitation	Genotoxic Effect		
	Preliminary Test	Main Test	_			
Absent						
Preliminary Test	> 5,000	-	> 5,000	Negative		
Main Test I	-	> 5,000	> 5,000	Negative		
Main Test II	-	> 5,000	> 5,000	Negative		
Present						
Main Test I	-	> 5,000	> 5,000	Negative		
Main Test II	-	> 5,000	> 5,000	Negative		

Remarks - Results Cytotoxicity and precipitation of the test substance were not observed with

or without metabolic activation during the study.

CONCLUSION The notified chemical was not mutagenic to bacteria under the conditions

of the test.

TEST FACILITY Safepharm (1997b)

B.11. Genotoxicity - simplified in vitro mammalian chromosome aberration test

TEST SUBSTANCE Notified chemical (≥ 99% in purity)

METHOD Mutagenicity Test: Chromosome Aberration Test Using Cultured

Mammalian Cells, Japan (simplified chromosome aberration test)

The test substance was examined at 1 sample per dose level.

Species/Strain Chinese hamster

Cell Type/Cell Line Lung fibroblasts (CHL/IU)

Metabolic Activation System S9 mix (commercially prepared from rat liver, induction system not

specified)

Vehicle Water

Remarks - Method The study was not conducted in compliance with GLP.

Metabolic Activation	Test Substance Concentration (µg/mL)	Exposure Period	Harvest Time
Absent			
Test 1	23.1, 46.3, 92.5, 185, 370*, 740*, 1480*	6 hours	24 hours
Test 2	23.1, 46.3, 92.5, 185, 370*, 740*, 1480*	24 hours	24 hours
Present			
Test 1	23.1, 46.3, 92.5, 185, 370*, 740*, 1480*	6 hours	24 hours

^{*}Cultures selected for metaphase analysis

RESULTS

Metabolic	Test Substance Concentration (μg/mL) Resulting in:				
Activation	Cytotoxicity in Preliminary Test	Cytotoxicity in Main Test	Precipitation	Genotoxic Effect	
Absent					
Test 1	-	> 1,480	> 1,480	Negative	
Test 2	-	> 1,480	> 1,480	Negative	
Present				-	
Test 1	=	> 1,480	> 1,480	Negative	

Remarks - Results Positive controls produced high numbers of aberrations, indicative of

sensitivity of the test system.

CONCLUSION The notified chemical was not clastogenic to Chinese hamster lung cells

treated in vitro under the conditions of the test.

TEST FACILITY CERI (2013)

B.12. Genotoxicity - in vitro mammalian chromosome aberration test

TEST SUBSTANCE Notified chemical (99.98% in purity)

METHOD OECD TG 473 In vitro Mammalian Chromosome Aberration Test

Species/Strain Chinese hamster
Cell Type/Cell Line Lung cell line (CHL)

Metabolic Activation System S9 mix (commercial Aroclor-1254 induced rat liver homogenate)

Vehicle Distilled water

Remarks - Method No significant deviations of the protocol were noted.

Concentrations of the test substance for the main tests were determined using a range-finding test. Cytotoxicity was < 50% at all concentrations

tested (up to $1,500 \mu g/mL$).

Metabolic Activation	Test Substance Concentration (µg/mL)	Exposure Period	Harvest Time
Absent			
Test 1	375*, 750*, 1500*	6 hours	24 hours
Test 2	375*, 750*, 1500*	24 hours	24 hours
Present			
Test 1	375*, 750*, 1500*	6 hours	24 hours
Test 2	375*, 750*, 1500*	6 hours	24 hours

^{*}Cultures selected for metaphase analysis

RESULTS

Metabolic	Test Substance Concentration (µg/mL) Resulting in:				
Activation	ctivation Cytotoxicity in Cytotoxicity in Pre		Precipitation	Genotoxic Effect	
	Preliminary Test	Main Test			
Absent					
Test 1	-	> 1,500	> 1,500	Negative	
Test 2	-	> 1,500	> 1,500	Negative	
Present					
Test 1	=	> 1,500	> 1,500	Negative	
Test 2	-	> 1,500	> 1,500	Negative	

Remarks - Results The positive controls produced a high number of aberrations, indicative of

sensitivity of the test system.

CONCLUSION The notified chemical was not clastogenic to Chinese hamster lung cells

treated in vitro under the conditions of the test.

TEST FACILITY KTR (2014d)

B.13. Genotoxicity – *in vivo* mammalian erythrocyte micronucleus test

TEST SUBSTANCE Notified chemical (99.98% in purity)

METHOD OECD TG 474 Mammalian Erythrocyte Micronucleus Test

Species/Strain Mouse/CrljOri:CD1 (ICR)

Oral – gavage Route of Administration

Vehicle Water

Remarks - Method No significant deviation of the protocol were noted.

> The test substance was orally administered twice at a 24-hour interval to the test animals and 5 animals per dose group were used in the study.

> Positive control (CP) was administered intraperitoneally once to the test animals.

Group	Number and Sex of Animals	Dose (mg/kg bw)	Sacrifice Time (hours)
I (vehicle control)	5 M	0	24
II (low dose)	5 M	500	24
III (mid dose)	5 M	1,000	24
IV (high dose)	5 M	2,000	24
V (positive control, CP)	5 M	70	24

CP = cyclophosphamide

Doses Producing Toxicity

No bone marrow toxicity was observed at any dose level for the notified chemical. No animals died and body weights of test animals were consistent with the negative control. A reduction in PCE/NCE ratio was seen in the positive control, indicating that it has bone marrow toxicity.

Genotoxic Effects No significant increases in micronucleated polychromatic erythrocytes (MPCEs) were observed at any dose level for the test or negative control

groups, indicating that there were no genotoxic effects.

Remarks - Results There were statistically significant increases in MPCEs in the positive

control group, confirming the sensitivity of the test system.

As no toxic effects of the test substance in the bone marrow were observed in the study, there was no clear evidence to demonstrate that the test substance was able to reach bone marrow.

CONCLUSION The notified chemical was not clastogenic under the conditions of this in

vivo chromosome aberration test.

TEST FACILITY

KTR (2014e)

APPENDIX C: ENVIRONMENTAL FATE AND ECOTOXICOLOGICAL INVESTIGATIONS

C.1. Environmental Fate

C.1.1. Ready biodegradability

TEST SUBSTANCE Notified chemical

METHOD OECD TG 301 C Ready Biodegradability: Modified MITI Test (I)

Inoculum Activated sludge

Exposure Period 28 days Auxiliary Solvent Not reported

Analytical Monitoring Measured biochemical oxygen demand (BOD). The test substance was

analysed by GC.

laboratory practice (GLP) principles. No significant deviations from the test

guidelines were reported.

RESULTS

Test	substance	Sodiu	m benzoate
Day	% Degradation	Day	% Degradation
7	Not reported	7	77.5
14	Not reported	14	84.7
28	-2.0	28	Not reported

sodium benzoate, reached the 60% pass level by day 7 indicating the suitability of the inoculum. It was not mentioned in the study that a toxicity control was included. The degree of degradation of the notified chemical after the cultivation period was a negative value. Therefore, the test substance cannot be classified as readily biodegradable according to the

OECD (301 C) guideline.

CONCLUSION The notified chemical is not readily biodegradable

TEST FACILITY KIT(2014)

C.2. Ecotoxicological Investigations

C.2.1. Acute toxicity to fish

TEST SUBSTANCE Notified chemical

METHOD OECD TG 203: Fish, Acute Toxicity Test – Semi-static Test

Species Medaka (Oryzias laptipes)

Exposure Period 96 hours
Auxiliary Solvent Not reported
Water Hardness 61 mg CaCO₃/L
Analytical Monitoring GC Analysis

Remarks - Method The test was conducted according to the guidelines above and good

laboratory practice (GLP) principles. No significant deviations from the test

guidelines were reported.

RESULTS

Nominal Concentration (mg/L)	Number of Fish	Cumulative mortality (%)				
		3 h	24 h	48 h	72 h	96 h
Control	10	0	0	0	0	0
100	10	0	0	0	0	0

LC50 > 90.8 mg/L at 96 h (Time-weighted mean of measured concentrations)

NOEC Not Applicable

Remarks – Results All validity criteria for the test were satisfied. The treatment concentration

was renewed at 48 hours during the 96-hour test period. The actual concentrations of the treatment were measured at 0 and 48 hours. The toxicity test was conducted as a limit test. The 96-hour LC50 was determined, based on the time-weighted mean of measured concentrations,

by visual observations.

CONCLUSION The notified chemical is not harmful to fish at the tested concentration.

TEST FACILITY Mitsubishi (2014b)

C.2.2. Acute toxicity to aquatic invertebrates

TEST SUBSTANCE Notified chemical

METHOD OECD TG 202 Daphnia sp. Acute Immobilisation Test – Static Test

Species Daphnia magna
Exposure Period 48 hours
Auxiliary Solvent Not reported
Water Hardness 242 mg CaCo₃/L
Analytical Monitoring GC Analysis

laboratory practice (GLP) principles. No significant deviations from the test

guidelines were reported.

RESULTS

Nominal Concentration (mg/L)	Number of D. magna	Cumulative % Immobilised	
		24 h	48 h
Control	20	0	0
100	20	0	0

EC50 > 93.6 mg/L at 48 h (Time-weighted mean of measured concentrations)

NOEC Not Applicable

Remarks - Results All validity criteria for the test were satisfied. The treatments

concentrations were measured at the beginning and end of the test. The toxicity test was conducted as a limit test. The 48-hour LC50 was determined, based on the time-weighted mean of measured concentrations,

by visual observations.

CONCLUSION The notified chemical is not harmful to aquatic invertebrates at the tested

concentration.

TEST FACILITY Mitsubishi (2014c)

C.2.3. Algal growth inhibition test

TEST SUBSTANCE Notified chemical

METHOD OECD TG 201 Alga, Growth Inhibition Test

Species Pseudokirchneriella subcapitata

Exposure Period 72 hours

Concentration Range Nominal: 100 mg/L
Auxiliary Solvent GC Analysis
Water Hardness Not reported

Analytical Monitoring Analysis of the test substance was not performed

Remarks - Method The test was conducted according to the guidelines above and good

laboratory practice (GLP) principles. No significant deviations from the test

guidelines were reported.

RESULTS

Biomass (72 h)		Growth (72 h) (Time-weighted mean of measured concentrations)		
$E_yC50 \ (mg/L)$	$NOE_yC(mg/L)$	$E_rC50 \ (mg/L)$	$NOE_rC(mg/L)$	
Not reported	Not reported	> 89.5	89.5	
Remarks - Results	deter The t the te rates calcu	validity criteria for the test were simined based on the time-weighted metreatments concentrations were measurest. The E _r C50 value was calculated but at 0, 24, 48 and 72 hour exposure alated by Student's t-test, subsequent nees. Statistical analyses were performance.	an measured test concentrations. ared at the beginning and end of by plotting the growth inhibition periods. The NOE _r C value was t to F test for homogeneity of	
Conclusion	The r	notified chemical is not harmful to alga	ae at the tested concentration.	
TEST FACILITY	Mitsu	ubishi (2014d)		

BIBLIOGRAPHY

- CERI (2013) Simplified Chromosome Aberration Test of DEGMEE Using Cultured Mammalian Cells (Study Number: P06-1455, December, 2013) Hita, Japan, Chemicals Evaluation and Research Institute (unpublished report submitted by the notifier).
- CICAD (2002) Diethylene Glycol Dimethyl Ether (Concise International Chemical Assessment Document 41, 2002), Geneva, World Health Organisation.
- Japan Oilstuff Inspectors' Corporation (2013a) Bacterial Reverse Mutation Test of DEGMEE (Study No.: AK13-21-0079, September, 2013) Japan, General Testing Research Institute, Japan Oilstuff Inspectors' Corporation (unpublished report submitted by the notifier).
- KIT (2014) Microbial Degradation Test of DEGMEE (Study No. KEG13133, March, 2014) Korea, Korea Institute of Toxicology (KIT) (Unpublished report submitted by the notifier).
- KTR (2013a) Acute Oral Toxicity Study of DEGMEE in SD Rats (Study Number: TBH-1659 (KG-2013-478)-Rev-1, November, 2013). Korea, Korea Testing and Research Institute (unpublished report submitted by the notifier).
- KTR (2013b) Acute Dermal Toxicity Study of DEGMEE in SD Rats (Study Number: TBH-1660 (KG-2013-479)-Rev-1, November, 2013). Korea, Korea Testing and Research Institute (unpublished report submitted by the notifier).
- KTR (2014a) Acute Dermal Irritation/Corrosion Study of DEGMEE in NZW Rabbits (Study Number: TBH-1661 (KG-2013-480), January, 2014). Korea, Korea Testing and Research Institute (unpublished report submitted by the notifier).
- KTR (2014b) Acute Eye Irritation/Corrosion Study of DEGMEE in NZW Rabbits (Study Number: TBH-1662 (KG-2013-481), January, 2014). Korea, Korea Testing and Research Institute (unpublished report submitted by the notifier).
- KTR (2014c) Skin Sensitisation Study of DEGMEE Using Buehler Test Method in Guinea Pigs (Study Number: TBH-1663 (KG-2013-482), February, 2014). Korea, Korea Testing and Research Institute (unpublished report submitted by the notifier).
- KTR (2014d) Chromosome Aberration Test of DEGMEE (Study Number: TBH-1667 (KG-2013-486), February, 2014). Korea, Korea Testing and Research Institute (unpublished report submitted by the notifier).
- KTR (2014e) Micronucleus Test of DEGMEE in Bone Marrow Cells of Male ICR Mice (Study Number: TBH-1668 (KG-2013-487)-Rev-1, April, 2014). Korea, Korea Testing and Research Institute (unpublished report submitted by the notifier).
- Mitsubishi (2013) A 14-Day Repeated Dose Oral Toxicity Study of DEGMEE in Rats (Study Number: P130588, September, 2013) Japan, Kumamoto Laboratory, Mitsubishi Chemical Medience Corporation (unpublished report submitted by the notifier).
- Mitsubishi (2014a) Combined Repeated Dose and Reproductive/Developmental Toxicity Test of DEGMEE by Oral Administration in Rats (Study Number: P130491, March, 2014) Japan, Kumamoto Laboratory, Mitsubishi Chemical Medience Corporation (unpublished report submitted by the notifier).
- Mitsubishi (2014b) Acute Toxicity Test of DEGMEE with Medaka (*Oryzias laptipes*) (Study No. A130980, January, 2014) Japan, Mitsubishi Chemical Medience Corporation (Unpublished report submitted by the notifier).
- Mitsubishi (2014c) Acute Immobilisation Test of DEGMEE with *Daphnia magna* (Study No. A130979, January, 2014) Japan, Mitsubishi Chemical Medience Corporation (Unpublished report submitted by the notifier).
- Mitsubishi (2014d) Growth Inhibition Test of DEGMEE with Green Algae (*Pseudokirchneriella subcapitata* (Study No. A130978, January, 2014) Japan, Mitsubishi Chemical Medience Corporation (Unpublished report submitted by the notifier).
- NOHSC (2004) Approved Criteria for Classifying Hazardous Substances, 3rd edition [NOHSC:1008(2004)]. National Occupational Health and Safety Commission, Canberra, AusInfo.
- Safepharm (1997a) Hisolve EDM: Acute Dermal Irritation Test in the Rabbit (SPL Project Number: 899/003, November, 1997) UK, Safepharm Laboratories Limited (Unpublished report submitted by the notifier).

Safepharm (1997b) Hisolve EDM: Reverse Mutation Assay "Ames Test" Using *Salmonella typhimurium* and *Escherichia coli* (SPL Project Number: 899/004, December, 1997) UK, Safepharm Laboratories Limited (Unpublished report submitted by the notifier).

- SWA (2012) Code of Practice: Managing Risks of Hazardous Chemicals in the Workplace, Safe Work Australia, http://www.safeworkaustralia.gov.au/sites/swa/about/publications/pages/managing-risks-of-hazardous-chemicals-in-the-workplace.
- SWA P39 Wide-format inkjet printing with solvent-borne inks. (Accessed on 18 September 2014 at http://www.safeworkaustralia.gov.au/sites/swa/whs-information/hazardous-chemicals/printers/controlguidance/digital/pages/p39wideformatinkjetprintingwithsolventborneinks).
- United Nations (2009) Globally Harmonised System of Classification and Labelling of Chemicals (GHS), 3rd revised edition. United Nations Economic Commission for Europe (UN/ECE), http://www.unece.org/trans/danger/publi/ghs/ghs rev03/03files e.html >.
- US EPA (2011) Estimation Programs Interface (EPI) SuiteTM for Microsoft® Windows, v 4.10. United States Environmental Protection Agency. Washington DC, USA, http://www.epa.gov/oppt/exposure/pubs/episuite.htm.
- US EPA (2014) Ethylene Glycol Ethers: Significant New Use Rule (40 CFR Parts 9 and 721, [EPA-HQ-OPPT-2009-0767; FRL-9915-61], RIN 2070-AJ52, December, 2014). EPA, US, Federal Register /Vol. 79, No. 241, Page 74639
- WIL Research (2013) Determination ¹H NMR Spectrum (Project 503661, November, 2013). The Netherlands, WIL Research Europe B.V. (Unpublished report submitted by the notifier).
- WIL Research (2014a) Determination of the IR Absorption Spectrum of DEGMEE (Project 504067, January, 2014). The Netherlands, WIL Research Europe B.V. (Unpublished report submitted by the notifier).
- WIL Research (2014b) Determination of Physico-Chemical Properties of DEGMEE (Project 503660, January, 2014). The Netherlands, WIL Research Europe B.V. (Unpublished report submitted by the notifier).